aceMachine learning prognostication in nasopharyngeal carcinoma: a european multicentre analysis of survival and risk of second malignancy
Nasopharyngeal carcinoma (NPC) is rare in Europe, and emerging data suggest poorer outcomes in Caucasian patients compared with Asian populations, highlighting the need for region-specific prognostic tools. Inflammation-based biomarkers and artificial intelligence show promise for risk stratification and prediction of survival and second primary cancers (SPCs). We conducted a retrospective multicentre study including 405 NPC patients from six European institutions. Demographic, clinicopathological, and haematolo…
Machine learning classifiers using demographic, clinicopathological and inflammatory markers predicted 5-year overall survival and second primary cancer occurrence in a European nasopharyngeal carcinoma cohort.
Retrospective design in a rare European disease with modest discriminative performance and limited cohort size of 405 patients.
Evidence
- Peer-reviewedEuropean Archives of Oto-Rhino-Laryngology2026-07-17
How should this claim be treated?
Truvace Impact Record TRV-2026-0246, v1: “Machine learning prognostication in nasopharyngeal carcinoma: a european multicentre analysis of survival and risk of second malignancy.” Truvace, 2026-07-17. /record/TRV-2026-0246 (accessed at citation time). sha256 6067dd02b0c249ba…
Calibration history
Every change to this record since certification, in the open. None yet — the reading has held since it entered the record.
Certified into the record
How to verify without trusting this page
Fetch the canonical text of any version from /api/record/TRV-2026-0246 and hash it yourself — for example shasum -a 256 on the saved canonical field. The result must equal content_hash, and each version’s text ends with prev:followed by the prior version’s hash (version 1 chains to 64 zeros). If a single character of any version had been altered since certification, the chain would not reproduce.